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PURPOSE: To study the epidemiology of oral 
candidiasis and the effect of treatment of thrush 
in human immunodeficiency virus (HIV)-infected 
patients. 
PATIENTS AND METHODS: We conducted a 
prospective observational study of 92 patients 
over 1 year, including a nonblinded, randomized 
treatment trial of thrush with clotrimazole troches 
or oral fluconazole. Oral sites were cultured 
monthly and when thrush occurred. Candida 
albicans strains were typed by contour-clamped 
homogeneous electric field (CHEF) 
electrophoresis. Changes in strains were 
evaluated over time and in regard to their 
associations with particular sites, episodes of 
thrush, relapse after treatment, and colonization 
of sexual partners. Susceptibility to fluconazole 
was tested and CHEF analysis was done on these 
strains to determine the epidemiology of 
fluconazole resistance. 
RESULTS: Yeasts colonized 84% of patients. C 
albicans accounted for 81% of all isolates and 
was separated into 34 distinct strains. Most 
patients had persistent carriage of 1 or 2 
dominant strains of C albicans. Three couples 
shared strains. Nineteen different C albicans 
strains caused 82 episodes of thrush in 45 
patients. CD4 c2OO/pL was associated with 
development of thrush. Clinical cure rates were 
similar with fluconazole (96%) and clotrimazole 
(91%), but mycologic cure was better with 
fluconazole (49%) than clotrimazole (27%). 
Following mycologic cure, colonization recurred 
with the same strain 74% of the time. 
Colonization ‘with Torulopsis glabrata and 
Saccharomyces cerevisiae increased after 
treatment with either drug, but these organisms 
were never a sole cause of thrush. In a subset of 
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35 patients followed for over 3 months in whom 
fluconazole susceptiblities were performed, 
minimum inhibitory concentrations (MICs) to 
fluconazole increased only in those on 
fluconazole prophylaxis. Clinical failure of 
fluconazole was associated with an MIC 264 
ug/mL in 3 patients, and with an MIC of 8 pg/mL 
in 1 patient. In 2 of these 4 patients, the prior 
colonizing strain developed fluconazole 
resistance. In the other 2, new resistant strains 
were acquired. 
CONCLUSIONS: Many different strains of C albicans 
colonize and cause thrush in patients infected 
with HIV. Patients are usually persistently 
colonized with a single strain, and recurrences 
following treatment are usually due to the same 
strain. Transmission of strains may occur 
between couples. Fluconazole and clotrimazole 
are equally effective in treating thrush, but 
mycologic cure occurs more often with 
fluconazole. 
Fluconazole resistance in C albicans occurs 
most often in patients who have low CD4 counts 
and are taking fluconazole prophylactically for 
recurrent thrush. Fluconazole resistance may 
occur through acquisition of a new resistant 
strain or by development of resistance in a 
previously susceptible strain. 
0 ral candidiasis is the most common fungal in- fection in patients with human immunodefi- 
ciency virus (HlV) infection’,” and is predictive of in- 
creasing immunosuppression.“,” Although studies 
have assessed the prevalence, treatment, and pro- 
phylaxis of oral candidiasis,1-7 few have looked pro- 
spectively at the epidemiology of colonization and in- 
fection with Candida albicans and the effects of 
treatment on colonizing and infecting strains.8-1” 
Those studies that have been reported have shown 
widely divergent results. 
Some studies have shown that patients with ac- 
quired immmunodeficiency syndrome (AIDS) have 
one predominant strain of C albicans,” but others 
have found multiple strains.lO~ll A change in coloniz- 
ing strains after treatment of thrush has been re- 
ported,” and so has recurrence of the same 
strains.12J4 
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C albicans resistance to azole antifungal drugs has 
been described infrequently but appears to be in- 
creasing.l”-ls The phenomenon of azole resistance 
has been seen almost entirely in AIDS patients re- 
ceiving fluconazole for long-term therapy or prophy- 
laxis for thrush. Most reports are isolated case re- 
ports. Few document susceptibility patterns before 
and after fluconazole therapy or relate such patterns 
to strain types. In one recent study from France, the 
authors showed development of resistance in the C 
aZb,icans strain causing thrush in 3 patients and ac- 
quisition of a new resistant C albicans strain in an- 
other patient.‘” However, the authors gave few clin- 
ical details about these patients. A recent study from 
the United States, using DNA karyotyping, docu- 
mented development of resistance to fluconazole in 
colonizing strains as well as acquisition of new re- 
sistant strains. l8 
In an attempt to define the epidemiology of oral 
candid&is, we studied a cohort of 92 HIV-infected 
patients over the course of 1 year. C aZbicans strains 
were karyotyped utilizing contour-clamped homoge- 
neous electric field (CHEF) electrophoresis,lg one of 
several new techniques for typing C albicans.1g-222 
Colonization and infection patterns, response to treat- 
ment, and effects of treatment on azole susceptibility 
were studied. 
PATIENTS AND METHODS 
Patients 
Ninety-two men with HIV infection who were fol- 
lowed in the Infectious Diseases Clinic at the Ann 
Arbor Veterans Affairs Medical Center were enrolled 
in the study, which was conducted from July 1991 
through June 1992. Samples for culture were taken 
from sexual partners of 10 of these patients to com- 
pare relatedness of colonizing C albicans strains. All 
patients gave written informed consent prior to entry 
into the study. 
Clinical Parameters 
On admission to the study, patients were evaluated 
regarding classification of HIV infection (AIDS, 
AIDS-related complex [ARC], or asymptomatic by 
criteria established prior to January 1993), risk fac- 
tors for HIV infection, prior episodes of thrush, prior 
antifungal therapy, and CD4 lymphocyte subpopula- 
tions. Each time a patient was seen in clinic (usually 
monthly, but more often if they had thrush), he filled 
out a questionnaire regarding alcohol, cigarette, and 
drug use, oral hygiene measures (frequency of brush- 
ing, flossing, and using mouthwash), and sexual prac- 
tices (frequency of oral, anal, or vaginal sexual in- 
tercourse, use of condoms, and number of partners). 
A careful examination was performed, including 
evaluation of lymph nodes and the oral cavity. 
Microbiologic Methods 
At initiation of the study, monthly thereafter, and 
whenever a patient had thrush, four oral sites (buccal 
mucosa, tongue, palate, and oropharynx) were 
swabbed with sterile rayon-tipped applicator sticks. 
The swabs were streaked directly onto one quadrant 
of a Sabouraud’s dextrose agar plate containing 50 pg 
gentamicin per mL. Within 1 to 2 hours, four-quadrant 
streaking with a loop was performed, and the plates 
were incubated at room temperature for 72 hours. 
Growth of yeasts was quantified (abundant, moder- 
ate, few, rare), different colony morphologies were 
noted, and single isolates of each colony type were 
subcultured onto Sabouraud’s dextrose agar slants. 
C albicans was identified by germ tube formation 
after incubation for 2.5 hours at 37°C in bovine serum. 
Germ tube negative strains were speciated using the 
API 20C yeast identification system (Analytab 
Products, Inc., Plainview, New York). All isolates 
were stored frozen at -70°C in Sabouraud’s broth and 
glycerol for further studies. 
Preparation of C albicans DNA 
Frozen stocks were thawed, streaked for isolation 
on Sabouraud’s dextrose agar plates, and incubated 
for 48 hours at 37°C. Yeast extract peptone dextrose 
(YEPD) broth, consisting of yeast extract 1 g/100 mL 
(Difco, Inc., Detroit, Michigan), Bacto Peptone 1 g/100 
mL (Difco), and dextrose 2 g/100 mL in deionized, dis- 
tilled HZ0 was inoculated with a single yeast colony 
and incubated for 48 hours at 37°C in 5% CO, atmos- 
phere. The DNA was prepared as described by 
Schwartz and Canto$3 and modified by Vazquez et al.“” 
CHEF Electrophoresis 
Portions of agarose plugs containing whole yeast 
cell DNA were loaded onto either a 15-lane or a 22- 
lane horizontal electrophoresis gel prepared with 
0.9% ultrapure agarose (Biological Research Labor- 
atories, Gaithersburg, Maryland) in 0.5x t&-borate 
EDTA (TBE) (Sigma) buffer. All gels contained chro- 
mosomal DNA from Saccharomgces cwevisiae 
(“Yeast chromosomal DNA,” Bio-Rad, Richmond, 
California) as an internal standard. Chromosomal 
separation was achieved on a Bio-Rad CHEF DR-II 
apparatus using the following parameters: 165V, 120- 
second switch time for 26 hours; followed by 125V, 
250-to 400-second switch time for 28 hours; followed 
by 85V, 750- to 900~second switch time for 26 hours. 
Running buffer was 0.5x TBE chilled to 13°C and 
changed with each change in parameters. Gels were 
stained with ethidium bromide, then photographed 
with ultraviolet transillumination. C albicans strain 
differentiation was performed by delineation of the 
pattern of bands existing between 700 and 2,200 kilo- 
bases (kb). For each isolate, the number of bands and 
340 October 1994 The American Journal of Medicine” Volume 97 
their position relative to the S cerevisiae standard 
bands were recorded. A library of banding patterns 
was established, and each isolate was given a code 
number, similar to the method of Pittet et al.‘” A strain 
was considered unique if it had a different number of 
bands or a different position of these bands relative 
to all previously described banding patterns. 
Treatment of Thrush 
For study purposes, an episode of thrush required 
the presence of adherent white plaques on oral mu- 
cosal surfaces and growth of yeast on cultures ob- 
tained from the oral cavity. Erythematous candidia- 
sis was not considered an episode because of 
concerns of objectively assessing the response to 
treatment. When thrush occurred, treatment group 
assignment was made based on the last digit of the 
patient’s social security number. Patients were as- 
signed to treatment with either oral fluconazole (200 
mg initially followed by 100 mg daily for a total of 14 
days) or clotrimazole troches (10 mg 5 times daily for 
14 days). One day after the end of therapy for each 
episode (on day 15), each patient was evaluated for 
clinical cure (resolution of all objective findings of 
thrush) and mycologic cure (absence of yeast on cul- 
ture of all 4 sites in the oral cavity). 
Patients failing therapy by clinical parameters 
(persistence of plaques) were switched to the other 
drug and treated for 14 days. This occurred in only 
2 patients. The episode was recorded as a failure 
for the initial drug given, and treatment with the sec- 
ond drug was evaluated as a new episode. Further 
episodes were treated with the drug to which the 
patient had been switched. Patients having 3 epi- 
sodes of thrush were put on prophylaxis with either 
clotrimazole or fluconazole and removed from the 
treatment study. Cultures were performed inter- 
mittently in those on prophylaxis to determine col- 
onizing strains. 
Fluconazole Susceptibility Studies 
Isolates from a subset of patients who received 
treatment for thrush were characterized in regard to 
susceptibility to fluconazole. The patients in whom 
susceptibility tests were performed were those who 
had C a&cans isolated prior to and/or at a first 
episode of thrush, follow-up for more than 3 months, 
and subsequent isolation of C albicans on follow-up 
cultures after treatment. 
Fluconazole susceptibilities were performed using 
a broth macrodilution system as recommended by the 
National Committee for Clinical Laboratory Stan- 
dards.2”-“G After growth on Sabouraud’s dextrose agar 
plates for 24 hours, organisms were inoculated into 
tubes containing RPMI-1640 (Roswell Park Medical 
Institute, Buffalo, New York) medium-buffered to a 
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TABLE I 
Patient Characteristics 
at the Time of Entry into the Study 
Characteristic Number (%) 
Risk factors for HIV 
Homosexual male 76 (83) 
Injectable drug use 12 (13) 
Heterosexual 4 (4) 
Classification of HIV 
AIDS 26 (28) 
AIDS-related complex 28 (31) 
Asymptomatic 38 (41) 
CD4 cell number 
<50 21 (23) 
50-200 16 (17) 
200-500 31 (34) 
>500 24 (26) 
HIV = human immunodeficiency virus; AIDS = acquired immunodeficlency 
syndrome. 
final pH of 7.0 with MOPS, achieving a final inoculum 
of approximately 2 X lo3 organisms per mL. 
Fluconazole concentrations ranged from 0.12 pg/mL 
to 64 pg/mL. The endpoint, minimal inhibitory con- 
centration (MIC), was read after 48 hours as an 80% 
decrease in growth, as described by Espinel-Ingroff, 
et alZ” 
Statistical Analysis 
Differences in outcome related to treatment and 
significance of risk factors for development of thrush 
were analyzed by the chi-square test. 
RESULTS 
Patients 
The mean age of the 92 men at entry into the study 
was 38.5 + 0.9 years. As noted, 26 (28%) had AIDS, 28 
(31%) had ARC, and 38 (41%) were asymptomatic 
(Table I). They were followed for a mean of 8.2 i 0.4 
months. At the end of the study, HIV status was again 
evaluated for each patient. In some cases, this was 
prior to June 1992 because patients moved (12), died 
(8), or developed another fungal infection requiring 
systemic antifungal treatment (2). At study termina- 
tion, 37 (40%) had AIDS, 31(34%) had ARC, and only 
24 (26%) remained asymptomatic. 
Colonization With Yeasts 
Altogether, 77 of the 92 patients (84%) had yeasts 
grown from their oral cavity on at least 1 occasion 
during the study. Of the 2,784 cultures performed, 
1,620 (58%) yielded yeasts, and a total of 1,965 iso- 
lates were recovered. C albicans was the predomi- 
nant isolate. It accounted for 81% of all isolates, was 
present in 83% of all patients, and occurred in 76 of 
77 patients whose cultures yielded yeasts (Table II). 
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TABLE II 
Yeasts Isolated From the Oral Cavity 
of HIV-Positive Patients 
Yeasts Number (%) Number (%) 
Isolated of Patients” of all Isolates 
Candida albicans 76 (83) 1,588 (81) 
Jorulopsis glabrata 13 (14) 182 (9) 
Saccharomyces cerevisiae 10 (11) 91 (5) 
Candida stellatoidea 10 (11) 21 (1) 
Candida tropicalis 2 (2) 20 (1) 
Other Candida species+ 10 (11) 14 (1) 
Non-Candida speciest 17 (18) 49 (2) 
‘Patients often had more than one species isolated; 15 patients never 
had a positive culture for yeast. 
+lncludes C. parapsilosis, C. paratropicalis, and C. rugosa. 
tlncludes Blasiosch!zomyces capitatus, Cryptococcus laurenti;, 
Cryptococcus untguttulatus, Sporobolomyces salmonicolor, and 
Prototheca zopfii. 
The next most commonly isolated yeasts were 
Torulopsis glabrata and Saccharomyces cerevisiae. 
Only 15 of 92 patients (16%) remained negative for 
yeasts in their oral cavity throughout the study. Ten 
of these 15 had asymptomatic HIV infection, 4 had 
ARC, and 1 had AIDS. Ten had CD4 counts >5OO/pL, 
and 5 had between 200 and 500 CD4 cells/pL. 
The only risk factor found to be significantly asso- 
ciated with colonization with yeasts was a CD4 count 
<5OO/pL (P <O.OOOl). Alcohol, drug, or cigarette use, 
oral hygiene practices, and sexual practices were not 
associated with colonization. 
Typing of C albicans Colonizing Strains 
Sixty-six of the 76 patients with C albicans had typ- 
ing of their isolates performed. Isolates from several 
patients seen only once were not typed, and several 
isolates were lost in the laboratory. 
The total number of different strains of C albicans 
carried over the course of the year by the 66 patients 
whose isolates were typed was 34. One strain was 
most common. It was cultured from at least 1 site on 
at least 1 occasion from 49 (74%) of the 66, and found 
in 428 of 918 (47%) @pings. 
Among 52 patients who either never received anti- 
fungal therapy or who had cultures performed on 2 
or more occasions prior to therapy, 24 (46%) had per- 
sistent carriage of only 1 strain. Another 7 patients 
(14%) were colonized with 1 dominant strain, but also 
transiently carried other strains on 2 or more occa- 
sions. Twenty-one paGents (40%) had 2 or 3 dominant 
strains of C albicans present at all times. 
There were 45 patients who grew C albicans from 
all 4 oral sites on the first day that cultures were per- 
formed and had these isolates typed. Twenty-six 
(58%) had the same strain present in all 4 sites, 17 
(38%) showed 2 different strains, and 2 (4%) showed 
3 different strains at these different sites. 
Episodes of Infection 
Forty-five patients had 82 episodes of thrush over 
the course of the study. Twenty-six of them (58%) had 
AIDS, 15 (33%) had ARC, and 4 (9%) were asympto- 
matic at the time they developed thrush. The only risk 
factor found to be important for the development of 
thrush was a CD4 count <200&L (P <O.OOOl). There 
were no associations with the use of cigarettes, al- 
cohol, drugs, sexual practices, or oral hygiene. 
Objective evidence of thrush was strongly associ- 
ated with an increase in the number of sites in the 
oral cavity yielding C albicans (P <O.OOOl) and with 
abundant growth in culture (P <O.OOOl). All episodes 
of thrush were associated with C albicans, which 
was the sole pathogen in 63 episodes, and was mixed 
with other yeasts-usually T glabrata or S cere- 
visiae-in 19. 
The C dbicans strains were typed in 74 episodes 
of thrush. The most common colonizing strain was 
found in 41 (55%), and the second most common in 
22 episodes (30%). Altogether, a total of 19 different 
strains caused the 74 episodes of thrush. In 51 
episodes (69%), only 1 strain was present at the time 
of infection; in 18 episodes (240/o)), 2 different strains 
were present; and in 5 (7%), there were 3 different 
strains. In only 2 patients were the initial colonizing 
strains different from those that later caused the first 
episode of thrush. 
Response to Treatment 
Twenty-three patients were randomized to treat- 
ment with fluconazole and 22 to treatment with 
clotrimazole. The 2 treatment groups did not differ 
in regard to risk group for HIV infection, stage of 
HIV disease, or CD4 counts. Overall, the clinical re- 
sponse to therapy was excellent for both flucona- 
zole (96% cure) and clotrimazole (91% cure) (Table 
III). The mycologic cure rate was lower with clotri- 
mazole (27%) than with fluconazole (490/o), but this 
difference was not statistically significant. Relapse 
of thrush within 2 weeks of completion of treat- 
ment occurred after 7 episodes treated with clotri- 
mazole and after only 2 episodes treated with flu- 
conazole. Adverse effects did not occur with 
clotrimazole, and one patient developed a rash 
while on fluconazole. 
Colonization Following Treatment 
Seventeen patients in whom therapy eradicated 
yeast were followed for at least 2 months post- 
treatment. In this group, colonization with C albi- 
cans recurred after each of 23 episodes of thrush. 
After 17 episodes (74%), recolonization was due to 
the same C albicans strain which caused the infec- 
tion. In 3 instances (13%), a new C albicans strain 
occurred along with the prior strain, while, in an- 
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TABLE Ill 
Results of Treatment of Thrush With Fluconazole or Clotrimazole Troches 
Fluconazole Clotrimazole 
Number of patients randomized to treatment group 23 22 
Number of patients crossed over from other drug after first episode’ 4 1 
Number of episodes treated 47 
Clinical cure+ 45/4J (96%) 31,3::91%) 
Mycologic curer 22/45 (49%) 9/33 (27%) 
‘Patients crossed over from clotrimazole to fluconazole for treatment of subsequent episodes because of failure (21, presence of 
esophagitis on second episode (l), and investigator error (1). One patient crossed over from fluconazole to clotrimazole for treatment 
of a second episode because of development of a rash possibly due to fluconazole. 
Tlinical response not known for 1 patient receiving clotrimazole because of death from myocardial infarction on day 7 of therapy. 
Kultures not performed at the end of an episode of thrush in 2 patients in each group. 
other 3, a totally new C albicans strain appeared 
following treatment (Figure 1). 
New species of yeasts emerged following treatment 
of 24 episodes of thrush in 14 patients. After 10 
episodes in 8 patients, T glabrata emerged as the 
dominant yeast in the oral cavity. Five of the 10 had 
been treated with fluconazole and 5 with clotrima- 
zole. S cerevisiae also occurred following treatment. 
One patient received fluconazole on 2 occasions and 
both times had emergence of S cerevisiae as the dom- 
inant species, Another patient was treated 3 times 
with clotrimazole, and each time S cerevisiae 
emerged as the sole yeast in the oral cavity. The re- 
maining 4 patients had new Candida species isolated 
transiently following treatment. In contrast, only 2 pa- 
tients who had never received antifungal therapy had 
colonization with T glabrata or S cerevisiae over the 
course of the study. 
Strain Relatedness in Sexual Partners 
In 4 couples with 1 partner who was HIV-negative, 
only 1 HIV-negative partner had yeast cultured from 
the oral cavity. In 5 of 6 couples where both partners 
were HIV-positive, both partners had yeasts cultured 
from their oral cavity. The same C albicans strains 
were isolated from both partners in 3 of these couples, 
and different strains in 2. In 1 couple who originally 
were colonized with the same strain, 1 partner became 
colonized by a new strain after treatment with flu- 
conazole. In another couple who shared 2 strains, the 
dominant strain in the partner who had been treated 
with fluconazole was resistant to the drug. This strain 
ultimately became dominant in the other partner, but 
only after he, too, was treated with fluconazole. 
Fluconazole Susceptibilities 
Over the course of the year, a subset of 35 patients 
meeting criteria described in the Methods section had 
fluconazole susceptibilities and CHEF typing deter- 
mined for 213 unique C albicans isolates, excluding 
identical strains isolated from multiple oral sites on 
the same day. Strains isolated prior to therapy for 
..5 IO 15 20 
B 
Figure 1. A. CHEF electrophoresis pattern of isolates from a 
patient who did not demonstrate a change in C albicans strains 
following treatment of thrush with clotrimazole troches. Lanes 2, 4 
and 5 are isolates from the first episode of thrush, lanes 6-l 1 are 
isolates from the second episode of thrush 1 month later, and 
lanes 13-19 and 21-22 are isolates from the third episode of 
thrush and subsequent colonizing strains during daily prophylaxis 
with clotrimazole. Lanes 3, 12, and 20 are the Saccharomyces 
cerevisiae standard. All strains appear to be identical and 
represent the most common strain found in this study. B. CHEF 
electrophoresis pattern of isolates from a patient who had 
recurrent thrush with new strains of C albicans following treatment 
of thrush with fluconazole. Lanes 1, 2, and 4 are isolates from this 
patient’s second episode of thrush; lanes 5-J are from 
posttreatment cultures following treatment and show the same 
strain as before (lane 7) and 2 new strains (lanes 5 and 6). Lanes 
8-10 and 12-13 are isolates from the third episode of thrush and 
are the same as those which caused thrush during the second 
episode 2 months previously. Lanes 14-19 and 21-22 show 4 
different strains, one of which is the original strain, which emerged 
following therapy and during prophylaxis wrth fluconazole. Lanes 3, 
11, and 20 are the S cerevisiae standard. CHEF = contour- 
clamped homogeneous electric field. 
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Figure 2. Minimum inhibitory concentrations (MICs) for 213 
isolates from 35 patients treated for thrush. The percent of 
isolates at each MIC are shown. Rx = treatment 
thrush with clotrimazole (16) or fluconazole (15), fol- 
lowing therapy with clotrimazole (14) or fluconazole 
(al), and following prophylaxis with clotrimazole (4) 
or fluconazole (9) were compared in regard to MICs 
for fluconazole (Figure 2). 
Only strains from patients receiving fluconazole for 
prophylaxis changed MICs. The MIC required to in- 
hibit 90% of the isolates (MIC,,) increased from 0.5 
pg/mL prior to and after acute therapy to 8 pg/mL fol- 
lowing prophylaxis for a mean of 4.3 months. There 
were no changes in fluconazole MICs in patients on 
prophylaxis with clotrimazole. 
Within this subset of 35 patients, 4 had recurrent 
thrush during the year of the study and after. Three 
of the 4 were on fluconazole chronically and had CD4 
counts <2O/pL for more than 1 year. C albicans con- 
tinued to be the only organism isolated when they had 
thrush. Fluconwole MICs and CHEF typing were per- 
formed on all isolates from these 3 patients. The MICs 
for early isolates were 0.2 to 0.5 pg/mL. The MICs 
were 264 pg/mL when the patients had thrush unre- 
sponsive to fluconazole. 
These patients initially responded to higher doses 
of fluconazole. All required 800 mg of the drug daily, 
but all ultimately failed to respond to this dose. Two 
were subsequently treated successfully with intra- 
venous amphotericin B. One maintained the same 
CHEF strain throughout the entire period of study, 
which appeared to have developed fluconazole resis- 
tance (Figure 3). One acquired a new strain, which 
persisted and was fluconazole-resistant in vitro. The 
third had 4 sensitive strains, of which 3 disappeared 
and the fourth developed resistance to fluconazole 
and persisted. 
The fourth patient with recurrent thrush had a CD4 
count of 270&L and was not on chronic fluconazole 
when he acquired a new strain with an MIC of 8 pg/mL 
and clinical failure occurred. He appeared to have ac- 
quired the resistant strain from his sexual partner. 
The partner had taken fluconazole chronically, had 
thrush unresponsive to fluconazole, and had isolation 
of 2 resistant strains. Our patient subsequently lost 
this strain, and later episodes of thrush responded to 
fluconazole (Figure 3). 
COMMENTS 
This prospective study of 92 patients has helped de- 
fine the epiderniology of oral candidiasis, the most 
common fungal infection in HIV-positive patients. We 
found, as have others, that colonization and subse- 
quent infection was associated with diminishing CD4 
cell counts.‘” Sexual practices, oral hygiene mea- 
sures, alcohol, drug, and cigarette use were not as- 
sociated with colonization or infection. The overall 
colonization rate of 84% was elevated compared with 
normal populations or hospitalized patients, in whom 
rates are usually 40% to 60%.Z7a28 
Although we found that 1 strain of C albicans was 
more common than others, we identified 34 different 
strains in this cohort of patients. Some investigators 
have reported finding 1 dominant strain in HIV-posi- 
tive patients,g but most studies have shown that AIDS 
pat,ients harbor many different strains of C albi- 
cans.10,11,1;3,14 In general, studies that use molecular 
typing methods rather than biotyping methods have 
found a greater number of unique strains.‘“14 
Symptomatic thrush occurred only when C albi- 
cans was present. When another yeast was present 
along with C albicans, it was impossible to know if 
one or both were responsible for symptoms. However, 
no patient had symptomatic thrush at a time when 
only non-albicans species were present. In contrast, a 
report by PowdeilyZg noted that T glabrata, Candida 
payapsilosis, Candida krusei, and Candida tropi- 
calis can cause thrush in HIV-positive patients. Just- 
Niibling et a1”O found that Candida famata and T 
glabrata were associated with typical thrush in 1 pa- 
tient each, both of whom had been treated with flu- 
conazole previously. Although we frequently noted 
colonization with TgZabrata in patients who had been 
treated with either fluconazole or clotrimazole, re- 
current thrush in these patients was always associated 
with recovery of C albicans in culture. 
We found that after antifungal therapy, the strain 
that caused the infection was usually the one to re- 
colonize. New strains emerged in a few cases. 
Previous studies have yielded contradictory results 
on this issue, with Bruatto et all1 showing new strains 
occurring after treatment, and S&mid et alIz and 
Miyasaki et all4 finding the same strains. 
Colonization of sexual partners by C albicans de- 
pended on HIV status. Partners who were HIV-nega- 
tive remained free of C albicans. Three HIV-positive 
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couples were colonized with the same strain or com- 
bination of strains of C albicans. In one of these cou- 
ples, in which both partners carried the same two 
strains, treatment of our patient with fluconazole was 
associated with a switch from his dominant strain to 
the dominant strain carried by his partner, who had 
previously received fluconazole. These findings are 
similar to those of Miyasaki et al,lJ who found possi- 
ble transmission of strains from partner to partner. 
Both clotrimazole troches and oral fluconazole 
were effective for treatment of thrush, but flucona- 
zole produced mycologic cure more often than did 
clotrimazole. Relapses within a few weeks were more 
often noted after treatment with clotrimazole, a find- 
ing also noted by Koletar et al.’ Emergence of new 
species of yeast, especially T glabrata and S cere- 
visiae, was seen after treatment with either flucona- 
zole or clotrimazole. Most likely this reflects the rel- 
atively greater resistance of these species to azole 
antifungal drugs.‘ll~“” We did not see the emergence of 
C krusei in our patients, although this event has been 
noted in bone marrow transplant recipients receiving 
fluconazole chronically.a” 
Our finding that C albicans strains became more 
resistant to fluconazole is worrisome. Increasing re- 
sistance in vitro correlated with clinical failure in 4 
patients who were followed for 2 years. In 2 patients, 
it appeared that resistance developed in a strain 
which had previously been susceptible to flucona- 
zole. Bart-Delabesse et al”’ made a similar finding in 
3 of 4 AIDS patients, as did Pfaller et all8 in 1 of 29 
AIDS patients. Initially, 3 of our patients responded 
to higher doses of fluconazole; but when the MIC ex- 
ceeded 64 pg/mL clinical failure occurred despite 
dosages of 800 mg/d. Redding et alj’ have reported 
a similar experience. Ng and Denning”” have dis- 
cussed the problem of fluconazole resistance in AIDS 
patients and offered several treatment options, in- 
cluding ketoconazole or itraconazole, but ampho- 
tericin B has usually been required. 
Development of methods for differentiating strains 
of C albicans at a genetic level has facilitated defin- 
ition of the epidemiology of colonization in several 
different settings.1”x”6-40 CHEF methodology &as used 
by Pittet et al’” to type Candida isolates from patients 
in intensive care units and by Pfaller et al’* with iso- 
lates from AIDS patients with thrush. S&mid et a137 
used Southern blot hybridization procedures to probe 
for repetitive DNA sequences in a variety of different 
patient populations colonized with C albicans. Others 
have used restriction fragment enzyme analysis for 
epidemiologic studies of nosocomial acquisition of C 
albicans.;‘“,40 
These different molecular typing methods have 
proved useful in studies of the epidemiology of C. aZ- 
bicans colonization in patients with HIV infec- 
1 5 10 15 
A 
1 5 10 15 20 
ORAL CANDIDIASIS IN HIV INFECTION/SANGEORZAN ET AL 
Figure 3. A. CHEF electrophoresrs pattern of strains of Candida 
afbicans from a patient who developed clinical failure after chronic 
fluconazole use. Lanes 1, 2, and 4 are from March 1992 and have 
MlCs of l-Zug/mL. Lanes 5-7, from Aoril 1992, have MlCs of 0.5- 
2 ug/mL. Lanes 8-9, from May 1992, have MlCs of 16 ug/mL. 
Lanes 10-11, from February 1993, have MlCs >64 ug/mL. Lanes 
13-15, from Aprrl 1993, have MlCs >64 ug/mL. Lane 3 and 12 
are the Saccharomyces cerevlsiae standard. All isolates are the 
same strain. In February and again in April 1993, the patient had 
thrush while taking fluconazole 800 mg/d. 6. CHEF 
electrophoresis pattern of isolates from a patrent who acquired a 
new fluconazole resistant strain of C albicans from his sexual 
partner. Lanes 1, 2, and 4 were isolated in February 1992 from 
our patrent’s sexual partner and are 2 different strains, both with 
MlCs of 16 ua/mL. Lanes 5-10 are from our oatient from 
yl 
November 1991 to February 1992 and are the same strain, all 
with MlCs of 0.2-2 ug/mL. Lane 11, from Aprrl 1991, is the same 
strain the patient’s partner carried, and the MIC is 8 pg/mL. Lanes 
12 and 14-20. from Mav and June 1992. the same strain again. 
have MlCs of 4-8 pg/mc, and were assoc’iated with failure of-206 
mg of fluconazole daily. Lanes 3 and 13 are the S cerevisiae 
standard. CHEF = contour-clamped homogeneous electric field. 
MIC = minimum inhibitory concentration. 
tion.lZ~l”~lS In our study and several prior studies, 
these techniques have helped establish the number of 
colonizing and infecting strains in patients with 
HlV,13,14J8 the transmission of these strains from part- 
ners,” and the role of different strains in recrudes- 
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cent infection.l’,‘J,l”,ls DNA typing methods other than 
CHEF, or in combination with CHEF, very likely 
might have increased sensitivity for detection of 
strain differences. As these techniques become more 
refined, they should allow us to address further the 
important questions of whether azole resistance is 
due to changes in colonizing strains or acquisition of 
new strains, whether azole-resistant strains can be 
passed from patient to patient, and what influence the 
use of prophylactic antifungal drugs has on the spread 
of azole-resistant strains. 
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